REGULATORY

THU, NOV 24TH, 2022, 08:00 CET

RLS Global AB (publ) Interim Report, Q3, 2022

JULY 1^st – SEPTEMBER 30^th (Previous year in brackets)

• Net sales amounted to TSEK 198 (TSEK 132).
• Earnings before interest and taxes (EBIT) amounted to MSEK -5,2 (MSEK 6,2).
• Earnings per share after dilution at SEK -0,07 (SEK 0,09).
• Cash flow from operating activities amounted to TSEK -5 114 (TSEK -6 214).
• Liquid assets at the end of the period MSEK 3,7 (MSEK 16,4).
• Equity ratio was 77 % (86 %).

JANUARY 1^st–SEPTEMBER 30^th (Previous year in brackets)

• Net sales amounted to TSEK 904 (TSEK 472).
• Earnings before interest and taxes (EBIT) amounted to MSEK -16,4 (MSEK 3,98).
• Earnings per share after dilution at SEK -0,23 (SEK 0,06).
• Cash flow from operating activities amounted to MSEK -12,7 (MSEK -3,46).
• Liquid assets at the end of the period MSEK 3,7 (MSEK 16,4).
• Equity ratio was 77 % (86 %).

SUMMARY OF EVENTS DURING THIRD QUARTER

• RLS issues new shares by way of set-off, totaling TSEK 10 000.
• An article regarding ChloraSolv is published in Journal of Wound Care.

SUMMARY OF EVENTS AFTER THIRD QUARTER

• New CEO Björn Larsson starts October 1.
• RLS has raised liquid assets through a new issue in November 2022 (rights issue) of MSEK 29.4.
• The Swedish Medicines Agency has approved RLS’ application for pressure ulcers.
• RLS visits the conference Wounds UK in Harrogate, England.

TRADING PLACE AND CERTIFIED ADVISER
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17^th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.

CONTACT INFORMATION
Björn Larsson, CEO
E-mail: bjorn.larsson@rlsglobal.se
Telephone: +46 766 20 17 25

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 730 23 13 57

PUBLICATION
This information was submitted for publication through the agency of the above contact person, at 08.00 CET on November 24^th 2022.